Psilocybin and Mescaline - Molecule of the Month October 1999 [Archived version]
This is the Molecule of the Month entry for October 1999 about psilocybin and mescaline. It is a pdf archive version of the HTML webpage.
Bibliographic context
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic ResearchPsychedelic Medicine · 2025-12-18Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary FindingsPsychedelic Medicine · 2023-11-30India’s Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric TherapeuticsIndian Journal of Psychological Medicine · 2026-02-04PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trialPalliative Medicine · 2026-01-29Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 StudyPsychedelic Medicine · 2025-12-22Advancing treatment paradigms: the role of psilocybin in managing major depressive disorderAnnals of Medicine and Surgery · 2025-11-23Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialPLoS Medicine · 2025-09-18Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysisThe International Journal of Psychiatry in Medicine · 2025-04-24